B-cell chronic lymphocytic leukemia (B-CLL) is a malignant disease characterized by an accumulation of monoclonal CD5 þ mature B cells, with a high percentage of cells arrested in the G0/G1 phase of the cell cycle, and a particular resistance toward apoptosis-inducing agents. Dok1 (downstream of tyrosine kinases) is an abundant Ras-GTPase-activating protein (Ras-GAP)-associated tyrosine kinase substrate, which negatively regulates cell proliferation, downregulates MAP kinase activation and promotes cell migration. The gene encoding Dok1 maps to human chromosome 2p13, a region previously found to be rearranged in B-CLL. We have screened the Dok1 gene for mutations from 46 individuals with B-CLL using heteroduplex analysis. A four-nucleotide GGCC deletion in the coding region was found in the leukemia cells from one patient. This mutation causes a frameshift leading to protein truncation at the carboxyl-terminus, with the acquisition of a novel amino-acid sequence. In contrast to the wild-type Dok1 protein, which has cytoplasmic/ membrane localization, the mutant Dok1 is a nuclear protein containing a functional bipartite nuclear localization signal. Whereas overexpression of wild-type Dok1 inhibited PDGF-induced MAP kinase activation, this inhibition was not observed with the mutant Dok1. Furthermore the mutant Dok1 forms heterodimers with Dok1 wild type and the association can be enhanced by Lck-mediated tyrosine-phosphorylation. This is the first example of a Dok1 mutation in B-CLL and the data suggest that Dok1 might play a role in leukemogenesis.
Introduction
B-cell chronic lymphocytic leukemia (B-CLL) is the most common type of adult leukemia found in Western populations. The disease is characterized by an accumulation of monoclonal CD5 þ , CD23 þ mature B cells, with a high percentage of cells arrested in the G0/ G1 phase of the cell cycle. These cells have a severe defect in programed cell death due to high expression of antiapoptotic proteins, like bcl-2 family proteins bcl-2, bcl-xL, bax and mcl-1 or survival factors such as TRAF1, and TRAF2 (Schroeder and Dighiero, 1994; Kitada et al., 1998; Caligaris-Cappio and Hamblin, 1999; Munzert et al., 2002) . Signaling pathways such as signal transducer and activator of transcription 1 (STAT 1) and (STAT 3), phosphatidylinositol-3 kinase (PI-3K) or NF-kB have been found constitutively activated in B-CLL cells (Frank et al., 1997; Furman et al., 2000; Munzert et al., 2002; Ringshausen et al., 2002) . Activation of such pathways may contribute to the disease.
So far, no recurrent gene mutation has been found in B-CLL. Instead, numerous chromosomal abnormalities involving chromosomes 6q21-q23, 11q22.3-q23.1, 13q14, 17p13 or 2p13 have been identified, some of which have clinical significance (Nelms et al., 1998; Wyatt et al., 2000) . The p53 tumor-suppressor gene and the ATM gene have been found mutated in B-CLL and p53 mutations are associated with resistance to chemotherapy (El Rouby et al., 1993; Wattel et al., 1994; Schaffner et al., 1999; Stankovic et al., 1999) . Dok1 (downstream of tyrosine kinases), or p62Dok1, is a phosphorylated protein downstream of a wide range of protein-tyrosine kinases (PTKs) (Carpino et al., 1997; Yamanashi and Baltimore, 1997; Bhat et al., 1998) . Dok1 and the related proteins Dok2, Dok3, Dok4, Dok5 and the insulin receptor substrate (IRS) (Nelms et al., 1998; White, 1998; Cong et al., 1999; Lemay et al., 2000; Di Cristofano et al., 2001; Grimm et al., 2001; Cai et al., 2003; Favre et al., 2003) contain a pleckstrin homology (PH) domain at the N-terminus, a central phosphotyrosine-binding (PTB) domain and a C-terminal domain rich in proline and several tyrosinephosphorylation sites (Carpino et al., 1997; Yamanashi and Baltimore, 1997) . After tyrosine-phosphorylation, Dok1 can interact with other signaling molecules containing SH2 domains, such as Ras-GTPase-activating protein (Ras-GAP), SHIP1, Nck, Csk and the X-linked lymphoproliferative syndrome (XLP) gene product SH2D1A (Neet and Hunter, 1995; Noguchi et al., 1999; Sylla et al., 2000; Sattler et al., 2001) . Dok1 downregulates several cell signaling processes: for example, it inhibits MAP kinase activity, downregulates cell proliferation, affects T-and B-cell signaling and plays a role in activin-induced apoptosis (Tamir et al., 2000; Yamanashi et al., 2000; Di Cristofano et al., 2001; Martelli et al., 2001; Nemorin et al., 2001; Songyang et al., 2001; Wick et al., 2001; Zhao et al., 2001; Kato et al., 2002; Yamakawa et al., 2002) . Dok1 can also affect cell adhesion, spreading and migration (Noguchi et al., 1999; Hosooka et al., 2001) . Tyrosine phosphorylation and PH domain-mediated plasma membrane translocation are necessary for Dok1 function (Liang et al., 2002; Zhao et al., 2001) . Dok1 can suppress cell transformation and leukemogenesis in mice Wick et al., 2001) . Dok1 maps to human chromosome 2p13 (Nelms et al., 1998) , a region of chromosomal translocation associated with several forms of leukemia including B-CLL and Bcell acute lymphoblastic leukemia (B-ALL) (Sonnier et al., 1983; Yoffe et al., 1990; Inaba et al., 1991; Richardson et al., 1992; Nelms et al., 1998) . Thus, the function of Dok1 is likely to be altered in these malignancies.
In the present study, we examined whether Dok1 is mutated in 46 B-CLL cases. We found a four-nucleotide GGCC deletion in the coding region of the gene in leukemia cells from one patient. This mutation causes a frameshift leading to protein truncation at the carboxyl-terminus, with acquisition of a novel amino-acid sequence. In contrast to the wild-type Dok1 protein that has membrane/cytoplasmic localization, the mutant Dok1 accumulates in the nucleus and contains a functional nuclear localization signal (NLS). Whereas the wild-type Dok1 downregulates PDGF-induced MAP kinase activation, the mutated Dok1 in CLL has no, or only a slightly increased effect on MAP kinase activity. These results imply that Dok1 may play a role in the development of B-CLL.
Results
Frameshift mutation in the coding region of Dok1 in B-CLL cDNAs isolated from lymphocytes of 11 healthy individuals and from tumor samples of 46 B-CLL patients were investigated for the presence of mutations in the Dok1 gene. The entire coding sequence was amplified using the primers listed in Table 1 and the PCR products were subjected to heteroduplex analysis. No abnormality in migration was observed for any PCR fragment except for one obtained with F4/R4 primers (see Table 1 ). With this set of primers, a different electrophoretic mobility was seen for B-CLL patient number 13, where the fragment migrated faster than in the other samples (Figure 1a , lane 3 and data not shown). Sequence analysis of this fragment revealed a four-nucleotide GGCC deletion at position 683 in exon 5 (amino acid 221) of the coding sequence of Dok1 (GenBank Dok1 cDNA Accession No. NM-001381) ( Figure 1b ). This mutation was confirmed by amplifying and sequencing a longer cDNA fragment from CLL13 spanning nucleotide 683 (data not shown). The GGCC deletion was not detected in the nucleotide sequence of cDNAs from normal individuals (Figure 1b , and data not shown). The mutation generates a frameshift and premature termination of the encoded Dok1 protein, with the generation of a hybrid truncated Dok1 protein with 298 amino acids and a theoretical molecular mass of 33 kDa (Figure 1b, c) . This predicted mutant protein, referred to as Dok1-CLL13, shares a 220 amino-acid sequence with wild-type Dok1, comprising the PH domain at the N-terminus and part of the PTB domain in the middle. However, as a result of the frameshift, Dok1-CLL13 contains a unique 78 amino-acid sequence at the C-terminal region that is not present in wild-type Dok1 (Figure 1c, d) . Notably, the new sequence, which has no significant homology with any protein in the GenBank, contains a stretch of 14 basic amino acids (Figure 1d ) that may affect the subcellular localization and the potential function of Dok1-CLL13 (see below). Thus the Dok1 gene can be altered in CLL.
Cloning and expression of Dok1-CLL13
In order to obtain insight into the possible function of the mutant Dok1 protein, a cDNA fragment amplified from CLL13 using F1A/R5 primers (see Table 1 ) was cloned in a TA plasmid vector (see Materials and methods). After transformation, plasmid DNAs extracted from several independent bacterial clones were purified and sequenced (data not shown). All the plasmids showed an identical GGCC deletion in the Dok1 sequence. Consistent with our previous observation (Figure 1b) , this result implies that no wild-type sequence of Dok1 exists in the cDNA of CLL13. We could not determine whether the GGCC deletion was present in the germ-line, because no normal tissue samples from patient CLL13 were available. Efforts to isolate adherent cells (macrophages) by cultivating the leukemia sample of patient CLL13 for genetic analyses were unsuccessful. Next, the entire coding region of Dok1 from CLL13 was inserted into the expression vector pcDNA3-Flag in frame with the FLAG epitope to obtain pcDNA3-Flag-Dok1-CLL13 (see Materials and methods). This plasmid construct was transfected into 293T cells, and 2 days after transfection, cell lysates were subjected to Western blot analysis using the M5 anti-Flag antibody (Figure 2a) . No protein was expressed from empty vector and wild-type Dok1 was expressed efficiently, as expected. The mutant Dok1-CLL13 was expressed in 293T cells as a protein with a molecular mass of about 35 kDa, close to the expected size of 33 kDa. Compared to wild-type Dok1, the level of Dok1-CLL13 expression was relatively low and this was observed in several independent experiments (see below and data not shown). These results suggest that the CLL mutant protein could be stably expressed in cells, albeit at a lower level than the wild type.
Dok1-CLL13 protein accumulates in the nucleus
In order to determine the subcellular localization of Dok1-CLL13, we first generated 293 cell lines stably expressing F-Dok1-wild type and F-Dok1-CLL13. A cell line containing empty vector was also obtained. Several selected clones expressed similar levels of Dok1 and Dok1-CLL13 proteins ( Figure 2b and data not shown). Again the level of expression of Dok1-CLL13 was lower than that of the wild-type protein (Figure 2b , compare lanes 5-6 to lanes 3-4). No cell lines expressing Dok1-CLL13 at the level of wild-type Dok1 were obtained. To determine the subcellular localization of Dok1-CLL13, cells were fractionated into cytosolic/ membrane (C) and nuclear (N) fractions, and analysed by Western blot ( Figure 2c ). As previously reported ), Dok1-wild type is predominantly a cytoplasmic protein with a small percentage found in the nucleus (Figure 2c , lanes 5 and 6). In contrast, Dok1-CLL13 seemed to be distributed between cytoplasm and nucleus, with a significant fraction accumulating in the nucleus (Figure 2c , compare lanes 9 to lanes 7 and 8).
The presence of Dok1-CLL13 in the cytoplasmic fraction could be due to contamination from the nuclear Black circles indicate tyrosine residues that can be phosphorylated by tyrosine kinase, and P indicates proline residues in the C-terminal region. Dok1-CLL13 is truncated at its C-terminus as a result of a frameshift and the hatched box indicates the new sequence of 78 amino acids. (d) The 298 amino-acid sequence of Dok1-CLL13 is shown. The boxed sequence designates the PH domain, and the change of amino-acid sequences due to the frameshift is indicated in bold letters. Basic amino acid, arginine (R) and lysine (K) residues are underlined Dok1 mutation in B-CLL S Lee et al fraction, as a proportion of nucleolin was also found in the cytoplasmic fraction ( Figure 2 , compare lanes 3, 6 and 9 to lanes 2, 5 and 8). Therefore, Dok1-CLL13 is basically a nuclear protein and the localization in the nucleus can probably be attributed to the new sequence at its carboxyl-terminus (see below). To further study the subcellular localization of Dok1-CLL13, the entire coding region of the protein was cloned in frame with GFP in a pGFP expression vector. The GFP versions of Dok1 and its PH domain (Dok1 (1-150), as well as the N-terminus region, Dok1-CLL13 (1-220) and in the C-terminus region, Dok1-CLL13 (221-298) of Dok1-CLL13, were also generated ( Figure 3a ). These plasmid constructs were transfected into 293T cells and the protein expression was evaluated by immunoblotting. As shown in Figure 3b , all the proteins were well expressed in 293T cells with the expected sizes. Again, the GFP-Dok1-CLL13 and its derivative proteins had lower expression levels compared to GFP, GFP-Dok1 or GFP-Dok1 (1-150) ( Figure 3b , lanes 4-6). We next examined the subcellular localization of these GFP fusion constructs. As shown in Figure 2 Expression of the Dok1-CLL13 protein and fractionation study. (a) Equal amounts of expression plasmids, pcDNA3 vector (lane 1), pcDNA3-F-Dok1 (lane 2) and pcDNA3-F-Dok1-CLL13 (lane 3) were transiently transfected into 293T cells and 48 h after transfection, cellular lysates were subjected to immunoblotting using M5 anti-Flag. F-Dok1 and F-Dok1-CLL13 proteins are indicated. (b) pcDNA3 vector (lanes 1 and 2), pcDNA3-F-Dok1 (lanes 3 and 4) and pcDNA3-F-Dok1-CLL13 (lanes 5 and 6) were stably transfected into 293 cells, and lysates were prepared from representative clones and then immunoblotting was performed using M5 anti-Flag and mouse anti-b-actin as a loading control. FDok1, F-Dok1-CLL13 and b-actin proteins are indicated. (c) Total lysates (L) (lanes 1, 4 and 7), cytoplasmic (C) (lanes 2, 5 and 8) and nuclear (N) (lanes 3, 6 and 9) fractions from 293 stable cell lines expressing F-Dok1, F-Dok1-CLL13 and from the control empty vector cells were prepared. Immunoblotting was performed using M5 anti-Flag, rabbit antinucleolin and rabbit anti-b-tubulin. The cytoplasmic protein b-tubulin in the cytoplasmic fraction and the high proportion of the nuclear protein nucleolin in the nuclear fraction provided controls for the experiment. F-Dok1, F-Dok1-CLL13, b-tubulin and nucleolin proteins are indicated these results indicate that the mutant Dok1 found in CLL disease localizes in the nucleus, in contrast to wildtype Dok1, and more importantly, that the accumulation in the nucleus is attributable to the unique sequence in the C-terminal region of the protein. This region may contain an NLS that directs the protein to the nucleus (see below). Furthermore, the data indicate that the Cterminal region of Dok1-CLL13 has a dominant effect over the PH domain to concentrate the protein in the nucleus rather than in the cytoplasm or membrane.
Dok1-CLL13 contains a functional NLS
The unique C-terminal region of Dok1-CLL13 contains 14 basic amino-acid residues whose spacing is reminiscent of NLS. Indeed, the alignment of the Dok1-CLL13 amino-acid sequence from 233 to 253 with the sequence of bipartite NLSs from nucleoplasmin, human GADD34 or herpes simplex-1 or -2 nuclear protein g 1 34.5 (Cheng et al., 2002) , strongly suggests that Dok1-CLL13 contains a potential bipartite NLS at its Cterminus ( Figure 5a ). In order to determine whether the region between 233 and 253 contained a functional NLS sequence, and if the conserved arginine residues were important for the nuclear localization, GFP-Dok1-CLL13 mutants with R233 and R234, R251 and R252, or R233, R234, R251 and R252, replaced by alanines were generated (Figure 5b ). Transient transfection in 293T cells followed by immunoblot analysis showed that GFP-Dok1-CLL13 and its R to A mutant forms were expressed at similar levels ( Figure 5c ). Confocal microscope studies showed that GFP-Dok1-CLL13 (R233A, R234A) and GFP-Dok1-CLL13 (R251A, R252A) behaved like GFP-Dok1-CLL13 and localized in the nucleus (Figure 6j-o) . These results indicate that neither mutation of R233 and R234 on the one hand, nor mutation of R251 and R252 on the other hand, is sufficient to abolish the nuclear localization of Dok1-CLL13. However, converting all four conserved arginine residues (R233, R234, R251 and R252) to alanines relocalized GFP-Dok1-CLL13 from the nucleus to the cytoplasm, with strong accumulation in the plasma membrane (Figure 6p-r) . Similar results were obtained using U2OS cells (data not shown). The particular concentration of the protein in the membrane is the consequence of the major effect of the PH domain due to the absence of a functional NLS. These data strongly indicate that Dok1-CLL13, due to the frameshift mutation, has acquired a functional NLS and that the four conserved arginine residues R233, R234, R251 and R252 are required for efficient nuclear localization, which is consistent with the bipartite form of NLS.
Dok1-CLL13 is impaired to inhibit MAP kinase activation
Dok1 acts as a negative regulator of MAP kinase activation and inhibits cell proliferation Hosooka et al., 2001) . To examine the effect of Dok1-CLL13 on MAPK activation, 293 cells stably expressing F-Dok1 and F-Dok1-CLL13, and the control cell line containing empty vector, were stimulated by PDGF at different time points. After stimulation, the lysates were subjected to Western blot analysis with rabbit antiphospho Erk1/2. Activation of MAP kinase Erk1/2 by PDGF occurred in the control cell line 5 min after stimulation, reaching a peak at 10 min before declining to the basal level (Figure 7a ). Whereas PDGFinduced Erk1/2 phosphorylation was much attenuated in cells overexpressing wild-type Dok1 (Figure 7a ), phosphorylation of Erk1/2 was normal or slightly elevated in cells that overexpressed Dok1-CLL13. Since the level of expression of Dok1-CLL13 was always low compared to the wild-type protein, we cannot exclude the possible inhibition of Erk phosphorylation when Dok1-CLL13 is expressed a high level (Figure 7a ). Nevertheless, Dok1 mutated in CLL lost its ability to inhibit MAP kinase activity due to an intrinsic loss of function, or a low level of expression. To check whether other signaling pathways are affected by Dok1-CLL13, tumor necrosis factor-alpha (TNF-a)-mediated phosphorylation and degradation of IkBa, the inhibitor of NF-kB, was evaluated. The phosphorylation and degradation of IkBa occurred similarly in the control cells, as well as in cells expressing Dok1 or Dok1-CLL13 after stimulation by TNF-a (Figure 7b ). This indicates that like wild-type Dok1, Dok1-CLL13 has no effect on the TNF-a-induced NF-kB activation pathway, as monitored by IkBa phosphorylation and degradation. Figure 6 Dok1-CLL13 has a functional NLS. GFP plasmid constructs described in Figure 5b were used for transfection into 293T cells. At 48 h after transfection, cells were treated as in Figure 4 . GFP, PI staining and merged image is shown Dok1 mutation in B-CLL S Lee et al Dok1-CLL13 is tyrosine-phosphorylated and forms heterodimers with wild-type Dok1
Dok1 is a tyrosine-phosphorylated protein (Carpino et al., 1997) . To determine whether Dok1-CLL13, which contains the PH and part of the PTB domain with five tyrosine residues (Figure 1d ), can be tyrosine phosphorylated, 293 cells stably expressing F-Dok1 and FDok1-CLL13 were stimulated with pervanadate, an inhibitor of tyrosine phosphatases. As shown in Figure 8a , tyrosine phosphorylation of F-Dok1-CLL13 was induced after pervanadate stimulation. The extent of tyrosine phosphorylation of F-Dok1-CLL13 is lower (5 tyrosine residues) than in F-Dok1 (15 tyrosine residues) (van Dijk et al., 2000) . To determine which tyrosine kinases can phosphorylate Dok1-CLL13, p210
Bcr-Abl , the Src family members c-Src, Lck and the Src inhibitor kinase Csk were tested. Whereas p210 Bcr-Abl , c-Src, Csk and Lck efficiently phosphorylated F-Dok1, F-Dok1-CLL13 was phosphorylated only by Lck (Figure 8b ), suggesting that one or several tyrosine residues in Dok1-CLL13 are targets for Lck, but not for Abl, Src or Csk in 293T cells. However, it has been reported that Dok277 containing the first 277 amino acid of Dok1 can be tyrosine phosphorylated by Src in NIH3T3 cells (Songyang et al., 2001) . Since Dok1-CLL13 contains the same tyrosine residues as Dok277, tyrosine phosphorylation of Dok1-CLL13 was examined in NIH3T3. As in 293T cells, only Lck phosphorylated Dok1-CLL13 in NIH3T3 cells (data not shown). This suggests that the failure of Abl, Src or Csk to phosphorylate Dok1-CLL13 is not dependent on the cell type, but resulted from the structure of Dok1-CLL13 protein. In view of homodimerization of Dok1 (Songyang et al., 2001) , heterodimerization of Dok1-CLL13 and wild-type Dok1 was examined by transfection in 293T cells. Both the endogenous Dok1 and the overexpressed myc-Dok1 associated with F-Dok-CLL13 (Figure 8c , lanes 1, 2, 5 and 6 and data not shown). This association increased in the presence of Lck (Figure 8c , compare lanes 5 and 6), indicating that tyrosine phosphorylation mediated the interaction (Songyang et al., 2001) . Remarkably, coexpression of myc-Dok1 reproducibly enhanced the tyrosine phosphorylation of F-Dok1-CLL13 by Lck (compare lanes 2 and 6). In addition, the phosphotyrosine content of F-Dok1-CLL13 was more pronounced than that of the coexpressed myc-Dok1 (Figure 8c , compare F-p-Dok1-CLL13 to Myc-p-Dok1 in lane 6). Taken together, these Bcr-abl , c-Src, Csk and Lck as indicated. At 1 day after transfection, lysates were immunoprecipitated and immunoblotting was performed as in (a). (c) 293T cells were transfected with F-Dok1-CLL13 alone or with the indicated combinations of Myc-Dok1 and Lck. At 1 day after transfection, cell lysates were prepared and small fractions were used to determine Dok1 levels by immunoblot analysis. The remaining portion of the lysates were immunoprecipitated and immunoblotting was performed as in (a) using mouse anti-pTyr, anti-Dok1 and anti-Flag Dok1 mutation in B-CLL S Lee et al results indicate that Dok1 either stimulates the kinase activity of Lck towards Dok1-CLL13, or recruits an endogenous kinase that can phosphorylate Dok1-CLL13. It also suggests that F-Dok1-CLL13, with its much lower tyrosine content, is probably a preferential substrate for Lck compared to Dok1 in a tripartite complex Lck/Dok1/Dok1-CLL13.
Discussion
Dok1 is known to be a negative regulator of several cell signaling pathways: it inhibits cell proliferation, downregulates MAP kinase activity and inhibits cell transformation and leukemogenesis (Yamanashi et al., 2000; Di Cristofano et al., 2001; Songyang et al., 2001; Wick et al., 2001; Zhao et al., 2001) . In addition, the localization of the Dok1 gene at 2p13, a chromosomal region rearranged in leukemia (Nelms et al., 1998) suggests that changes in its structure are expected during tumor initiation or promotion. However, a direct role of Dok1 in human malignant disease has yet to be demonstrated. Our data provide evidence for the first time that mutation of the Dok1 gene may be involved in human tumors like B-CLL. A four-nucleotide GGCC deletion at position 683 in the coding sequence of the Dok1 gene was found in one of the 46 B-CLL patients analysed. No chromosomal alteration affecting 2p13 region was detected in this patient (Dumontet et al., unpublished observation). The mutation, which was not found in healthy individuals or in tumor samples from 52 patients affected by acute myeloid leukemia (AML) (Lee et al., unpublished results), could be a rare event restricted to a small set of B-CLL. The GGCC deletion results in a frameshift in the Dok1 coding sequence, generating a hybrid Dok1 protein truncated at the Cterminus, with unique properties. In this mutant protein, the C-terminal region of wild-type Dok1 from amino acid 220-481 is replaced by a novel sequence of 78 amino acids with no significant homology in GenBank (Figure 1) . In contrast to wild-type Dok1, which localizes in the cytoplasm and membrane, the mutant protein, Dok1-CLL13, accumulates almost exclusively in the nucleus (Figure 4) , due to the presence of a bipartite NLS in the unique C-terminal region of Dok-CLL13. Since the mutant protein can be stably expressed in 293 cells, we presume that it is expressed in leukemia cells as well, even though this was not verified due to a lack of suitable tumor samples and appropriate antibodies. Several attempts to immortalize the few available CLL-13 B-cells with Epstein-Barr (EBV), in order to identify the native CLL13 protein, were unsuccessful. Converting the four-conserved arginine residues R233, R234, R251 and R253 to alanines in the putative NLS reversed the Dok1-CLL13 nuclear localization, bringing the protein into the cytoplasm with a pronounced concentration in the plasma membrane ( Figure 6) .
A truncated Dok1 isoform referred to as p22Dok del has recently been reported (Hubert et al., 2000) . This protein is coexpressed with the full-length Dok1 protein in various cell types, including immortalized lymphoblastoid cell lines and mononuclear cells from healthy individuals, as a result of alternative splicing (Hubert et al., 2000) . The 35 kDa protein Dok1-CLL13 found in B-CLL is different from p22Dok del at the amino-acid sequence level. In addition, p22Dok del lacks any potential NLS that could cause its localization in the nucleus. Thus the 35 kDa protein Dok1-CLL13 is a novel mutated form of Dok1 found in B-CLL disease.
The frameshift mutation identified in B-CLL is likely to affect several important functional properties of Dok1 that are ascribed to its C-terminal region. In fact, this region has been shown to be important for Dok1 to suppress cell proliferation and cell transformation (Hosooka et al., 2001; Songyang et al., 2001; Shah and Shokat, 2002) . In addition, tyrosine residues 296 and 315, which are necessary for Dok1 to interact with Ras-GAP in order to downregulate MAP kinase activity (Songyang et al., 2001; Shah and Shokat, 2002) , are lost in Dok1-CLL13. Consistent with this observation, PDGF-induced MAP kinase activation is not affected, and is even slightly increased in 293 cells expressing Dok1-CLL13, compared to wild-type Dok1, which has an inhibitory effect (Figure 7a ). On the other hand, NFkB signaling is not affected by either wild-type Dok1 or Dok1-CLL13 (Figure 7b ). Also tyrosine residues 296 and 362, known to be necessary for Dok1 to inhibit Srcinduced cell transformation (Songyang et al., 2001; Shah and Shokat, 2002) , are missing in Dok1-CLL13. In addition, partial loss of the PTB domain, which also plays a role in the inhibition of cell transformation (Songyang et al., 2001) , could contribute to affect Dok1 function in Dok1-CLL13. Dok1-CLL13 is a tyrosine-phosphorylated protein and among the tyrosine kinases Bcr-Abl, Src, Csk and Lck that phosphorylate efficiently wild-type Dok1, only Lck phosphorylated Dok1-CLL13 (Figure 8b) . The Lck-mediated Dok1-CLL13 phosphorylation increased in the presence of wild-type Dok1 and enhanced the heterodimerization of Dok1 and Dok1-CLL13 (Figure 8c ). Dok1 may enhance Lck activity toward Dok1-CLL13, either by conformation change, or by recruiting additional tyrosine kinases as it has been proposed for the increased tyrosine phosphorylation of Tec by Dok1 (van Dijk et al., 2000) . The tyrosine residue(s) of Dok1-CLL13 that can be phosphorylated by Lck remain to be determined. Tyrosine 203 of Dok1-CLL13 (and Dok1) (Figure 1 ) that is in the tyrosine binding motif (YXX(I/L/V) for Lck SH2 domain, could be a target for Lck (Nemorin and Duplay, 2000) . However, phosphorylation of tyrosine 146 present in the PTB domain of both Dok1 and Dok1-CLL13 can also be induced by Lck, since phosphorylation of this residue is necessary for Dok1 homodimerization (Songyang et al., 2001) . Therefore the fraction of cytoplasmic Dok1-CLL13 might associate with wild-type Dok1 through tyrosine 146 and act as a dominant negative to inhibit Dok1 function, and Lck can play an important role in this inhibition. Interestingly, Lck expression is known to be restricted to T cells, but it is frequently activated in B-cell neoplasias including CLL Dok1 mutation in B-CLL S Lee et al Jucker et al., 1991; Von Knethen et al., 1997) . Therefore, specific tyrosine phosphorylation of Dok1-CLL13 by Lck could be biologically relevant. Finally, the mislocalization of Dok1 and the relative low expression of the mutant protein may have a dramatic effect on the overall function of Dok1. It is also plausible that this mislocalization removed Dok1 from a signaling cascade important for its function. Thus, the mutation identified in B-CLL appears to inactivate Dok1. Low expression of wild-type protein due to methylation of the promoter region, or mutation in the key regulatory sequence is another mechanism leading to the inactivation of Dok1. Indeed, Dok1 expression has been found downregulated in the leukemia cells of a small subset of B-CLL patients (Galmarini et al., unpublished data). In contrast to most malignant diseases that are characterized by uncontrolled cell proliferation, B-CLL is believed to have a defect in the regulation of apoptosis and a lack of cell cycle progression (CaligarisCappio and Hamblin, 1999) . Therefore, it is possible that mutation of Dok1 in B-CLL does not necessarily imply the acquisition of an uncontrolled cell proliferation phenotype, but rather the prolongation of the chronic stage of the disease. Indeed, stable 293 cell lines expressing Dok1-CLL13 grow similarly to cell lines expressing wild-type Dok1, that is, at a low rate compared to control cells (Lee et al., unpublished observation). As a matter of fact, patient CLL13 was particularly resistant to a number of chemotherapeutic agents used in the routine treatment of B-CLL disease, such chlorambucil, fludarabine and CHOP chemotherapy. However the link between this observation and mutation of Dok1 in B-CLL remains to be established, as no significant difference in the cytotoxicity and apoptosis studies was observed between 293 cells expressing Dok1 or Dok1-CLL13 (Galmarini et al., unpublished data), probably due to the type of cells. It is worth noting that chromosomal rearrangements leading to a novel fusion protein with transcription activation properties are common in several forms of acute and chronic leukemia (Rabbitts, 1991) . In this context, the nuclear localization of Dok1-CLL13 might be functionally relevant. Nevertheless, since tumorigenicity is assumed to be a multistep process in which various genetic changes lead to tumor formation, the mutation of Dok1, in conjunction with other identified alterations, may be important in the progression and maintenance of a small fraction of B-CLL disease. Further studies on a larger scale are required to evaluate the potential role of Dok1 as a tumor suppressor in B-CLL and other leukemias.
Materials and methods

Patients
Blood samples were obtained from 46 patients with B-CLL obtained at the Department of Hematology of the Hospital Edouard Herriot (Lyon, France). Diagnosis of CLL was performed by an experienced cytologist and confirmed by immunophenotypic analysis using flow cytometry (Matutes score of 4/5 or 5/5). All samples contained more than 15 000 cells/ml, and more than 80% were leukemic cells. Normal blood samples were obtained from 11 healthy volunteers. Lymphoid cells were separated by Ficoll Hypaque gradient centrifugation. Patients and health individuals gave informed consent for this study.
RNA and cDNA preparation
Total RNA was isolated from lymphoid cells using TRIREAGENTt (Sigma, St Louis, MO, USA) according to the manufacturer's instructions. RNA was then dissolved in RNase-free H 2 O and stored at À801C. For synthesis of firststrand cDNA, 2 mg of total RNA was mixed with 500 ng of pD (N 6 ) primer (Amersham, London, UK) in a total volume of 12 ml, heated at 701C for 10 min and then cooled quickly on ice. A volume of 8 ml of a mixture including 100 mM DTT, 5 Â reverse transcriptase buffer, 10 mM dNTP and SuperScriptt II RNase H-Reverse Transcriptase (Invitrogen, Carlsbad, CA, USA) were added to the tube, and the reaction was incubated at 421C for 5 min before inactivation at 701C for 10 min. The synthesized cDNA mixture was diluted 1/20 with distilled water before mutation screening by heteroduplex analysis.
Heteroduplex analysis
The sequence of the primers used for amplification of Dok1 cDNA (GenBank Accession No. NM-001381) is shown in Table 1 . PCR reactions were conducted in a Perkin-Elmer 9600 thermal cycler. Briefly, about 50 ng cDNA were used as a template in a 15 ml reaction containing 1.0 U of Taq DNA polymerase (Invitrogen), 200 mM each of dGTP, dATP, dTTP and dCTP, 1.0 mCi of [a-
33 P]dCTP and 1 mM of primer (Amersham, London, UK). Cycles were as follows; 961C for 4 min, followed by 30 cycles of 961C for 30 s, adjusted annealing temperature for 30 s, 721C for 2 min, followed by 10 min at 721C. The PCR products were slowly cooled to room temperature. Samples mixed with loading buffer (95% formamide, 10 mM NaOH, 0.05% bromophenol blue, 0.05% xylene Cyanol) were run at room temperature on mutation detection enhancement (MDE) gel.
Direct sequencing analysis
The amplified DNA fragment was purified using a PCR product purification kit (Qiagen, Chatsworth, CA, USA). Purified products were sequenced using a Bigdye terminator kit (ABI PRISM DNA sequencing kit, Perkin-Elmer) and ABI 3100 DNA sequencer and the sequencing result was analysed with the BioEdit sequence alignment editor (Hall, 1999) .
Plasmids, cloning and mutagenesis
The Dok1 expression plasmid, pcDNA3-F-Dok1, has been previously described (Sylla et al., 2000) . F designates the presence of a FLAG epitope in the N terminus. To construct the expression plasmid pcDNA3-F-Dok1-CLL13, cDNA from patient CLL13 (patient no. 13 with chronic lymphocytic leukemia) was first amplified using PCR primers F1A and R5 (see Table 1 ). The PCR product was then cloned in TA cloning pCR4 vector using a TOPO TA cloning Kit (Invitrogen) to obtain pCR4-Dok1-CLL13. pcDNA3-F-Dok1 has two Bam-HI sites (nucleotides 476 and 1096) in the coding region and one NotI site at 3 0 in the pcDNA3 vector; pCR4-Dok1-CLL13 contained the BamHI site (position nucleotide 476) and a NotI site at 3 0 in the pCR4 vector. To obtain pcDNA3-F-Dok1-CLL13, the BamHI (position 476)/NotI fragments of Dok1 mutation in B-CLL S Lee et al pcDNA3-F-Dok1 were substituted by the corresponding fragment of pCR4-Dok1-CLL13 carrying the GGCC deletion at nucleotide 683. To construct pGFP-Dok1-CLL13, pcDNA3-F-Dok1-CLL13 was amplified using forward primer CLL13 (F)-EcoR 23 (5 0 -GGAATTCCATGGACGGAG-CAGTGATGGA-3 0 ) corresponding to amino acid 1 in the coding region of Dok1-CLL13 (underlining indicates an added EcoRI site) and the reverse primer, CLL13(R)-Kpn919 (5 0 -GGGGTACCCCCTAAGGGCTCAGCATACAGG-3 0 ) corresponding to amino acid 220 in the coding region of Dok1-CLL13 (underlining indicates an added KpnI site; italics indicate stop codon). PCR products were digested by EcoRI/ NotI and the fragment was inserted into EcoRI/KpnI sites in frame with GFP of the pEGFP-C1 vector (Clontech, Palo Alto, CA, USA). Similarly, pGFP-Dok1-CLL13 (1-220) was constructed using the forward primer CLL13 (F)-EcoR 23 and the reverse primer CLL13(R)-Kpn682 (5 0 -GGGGTACCCC CTAGGCCTCGAAAGAGAACATGA-3 0 (underlining indicates an added KpnI site; italics indicate stop codon) corresponding to amino acid 220 of the coding region of Dok1-CLL13. To construct pGFP-Dok1-CLL13 (221-298), the forward primer, CLL13 (F)-EcoR 683 (5 0 -GGAATTCCGCCGCTGCCCCTCAGGCCCT-3 0 ) (underlining indicates added EcoRI site) corresponding to amino acid 221 of the coding region of Dok1-CLL13 and the reverse primer CLL13(R)-Kpn919 were used. GFP-Dok1 CLL13 variants bearing specific mutations were obtained by PCR mutagenesis. pGFP-Dok1-CLL13 (R233A, R234A), pGFPDok1-CLL13 (R251A, R252A) and pGFP-Dok1-CLL13 (R233A, R234A, R251A, R252A) are Dok1-CLL13 mutants in which the respective arginine (R) residues at 233 and 234, or 251 and 252, or 233, 234, 251 and 252 were replaced by alanine (A). All mutations and constructs were confirmed by sequencing analysis. The expression plasmids for p210 bcr-abl , c-Src, Csk and Lck were obtained respectively from A-M Pendergast (Duke University, Durham, NC, USA), A August (Pennsylvania State University, Philadelphia, PA, USA), W Eckhart (Salk Institute, San Diego, CA, USA) and R Perlmutter (Merck & Co., Inc., Rahway, NJ, USA).
Cell culture and transfection
HEK 293 cells (adenovirus E1a-and E1b-transformed human embryonic kidney) and HEK 293 cells expressing simian virus 40 large T antigen (293T) were maintained in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS). For transient or stable transfection, 1 mg of empty vector pcDNA3, pcDNA3-Flag-Dok1 or pcDNA3-Flag-CLL13 was introduced into HEK 293 using a Superfect kit (Qiagen) according to the manufacturer's instructions. For stable transfection, G418 (800 mg/ml)-resistant colonies were selected and expanded. Protein expression was confirmed by immunoblotting using M5 anti-Flag mouse monoclonal antibody.
Antibodies
M5 anti-Flag mouse monoclonal antibody was obtained from Sigma. The rabbit polyclonal antibodies against phosphorylated Erk1/2, phosphorylated IkBa and total IkBa were purchased from New England Biolabs (Beverly, MA, USA). Rabbit antinucleolin antibody and goat antibodies against total Erk1/2 were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA), and rabbit anti-b-tubulin antibody was obtained from Roche (Mannheim, Germany). Monoclonal antibody against b-actin was purchased from ICN Biomedicals. Rabbit anti-Dok1 antibodies were obtained from R Kobayashi (MD Anderson Cancer Center, Houston, Texas, USA) and J Cambier (St Jude Children's Research Hospital, Memphis, TE).
Immunoprecipitation and Western blotting
Cultured cells were washed with ice-cold PBS and were lysed in an ice-cold lysis buffer (50 mM Tris-HCl, pH 7.4; 150 mM NaCl; 2 mM EDTA; 1% Nonidet P-40; 3% glycerol, 1 mM PMSF; 1 mM b-glycerophosphate, 5 mg/ml leupeptin, 2 mg/ml aprotinin; 1 mM sodium fluoride, 1 mM sodium orthovanadate) for 30 min on ice. The lysates were centrifuged at 14 000 r.p.m. for 20 min. Lysates were quantified using a protein assay reagent (BIORAD) and analysed on SDS-polyacrylamide gel. Immunoprecipitation was performed as previously described (Sylla et al., 2000) . Proteins on the gel were transferred to PDVF membranes and probed with antibodies. Membranes were then visualized by using chemiluminescent luminol reagents (Santa Cruz). The nuclear and cytoplasmic fractions were prepared as follows: 2 Â 10 6 of stably transfected cells were washed twice with ice-cold PBS and then lysed with cytoplasmic lysis buffer (20 mM HEPES, pH 7.6; 20% glycerol; 10 mM NaCl, 1.5 mM MgCl 2 ; 0.2 mM EDTA; 0.1% NP40; 1 mM DTT; 1 mM PMSF; 1 mM b-glycerophosphate, 5 mg/ml leupeptin, 2 mg/ml aprotinin; 1 mM sodium fluoride, 1 mM sodium orthovanadate). After 10 min on ice, lysed samples were centrifuged at 2000 r.p.m. for 4 min to recover the cytoplasmic fraction in the supernatant. The pellets were mixed with a nuclear lysis buffer (20 mM HEPES, pH 7.6; 20% glycerol; 500 mM NaCl, 1.5 mM MgCl 2 ; 0.2 mM EDTA; 0.1% NP40; 1 mM DTT; 1 mM PMSF; 1 mM b-glycerophosphate, 5 mg/ml leupeptin, 2 mg/ml aprotinin; 1 mM sodium fluoride, 1 mM sodium orthovanadate) incubated on ice for 30 min, and then centrifuged at 14 000 r.p.m. for 30 min to recover supernatant containing the nuclear fractions.
Confocal microscopy and immunofluorescence
Cells were seeded on a sterilized cover glass in six-well plates at 0.1 Â 10 6 cells per well. At 24-48 h after transfection with GFP expression plasmids, cells on the cover glass were washed twice with PBS and fixed with 4% paraformaldehyde for 10 min. Fixed cells were permeabilized with 0.1% Triton for 5 min, stained with propidium iodide (PI) and visualized using a Zeiss confocal LSM 510 microscope.
MAP kinase and NF-kB assays
Cells (0.4 Â 10 6 ) were seeded in six-well plates and cells were incubated in DMEM containing 10% FBS for 24-48 h. Cells were then stimulated with 20 ng/ml of platelet-derived growth factor (PDGF) (R&D System, Minneapolis, MN, USA) or 20 ng/ml of TNF-a (Sigma) at different times. After stimulation, cells were lysed in 200 ml of lysis buffer on ice for 30 min, and lysates were then subjected to immunoblotting analysis using specific antibodies for phosphorylated Erk1/2, total Erk1/2 proteins, phosphorylated IkBa, or total IkBa protein.
